A Multicenter Pilot Study of Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma
Sponsor study identifier
interventional
36
1 country
8
Study Start
May 2014
Actual (reported)Primary Completion
December 23, 2025
Actual (reported)Study Completion
December 23, 2025
Actual (reported)The purpose of this study is to assess the effectiveness of electronic skin surface brachytherapy (ESSB) for early stage basal or squamous cell carcinoma of the skin using a new device. This new device is Nucletron's Esteya Electronic Skin Surface Brachytherapy System. The investigators want to understand what effects, good and/or bad this device for delivering brachytherapy has on your skin cancer. The investigators also want to assess the safety, cosmetic results, the effects that ESSB has on quality of life and to correlate skin imaging with clinical response to ESSB.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 23, 2025
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2014
Actual (reported)May 5, 2014
Actual (reported)May 6, 2014
Actual (reported)December 23, 2025
Actual (reported)December 23, 2025
Actual (reported)efficacy of Electronic Skin Surface Brachytherapy (ESSB)
Efficacy will be measured by local control of the irradiated BCC/SCC three years after brachytherapy.
3 years
assess the cosmetic outcome of ESSB
Cosmetic outcome will be patient-reported and clinician-assessed after brachytherapy.
3 years
severity of adverse events
3 years
reported quality of life
3 years
The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Boca Raton Regional Hospital
Boca Raton, Florida, 33486, United States
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Consent only)
Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Commack (Consent only)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center
Christopher Barker, MD
Memorial Sloan Kettering Cancer Center
36 participants (actual enrollment reported by the registry).
First Submitted
May 5, 2014
First Posted
May 6, 2014
Study Start
May 2014
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Consent only)
Uniondale, New York, 11553, United States
December 23, 2025
Actual (reported)Study Completion
December 23, 2025
Actual (reported)Last Updated
December 30, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: